solution by Industry

End-to-End GMP Manufacturing Solutions for Oncology Drug Production

From injectable chemotherapy filling lines to oral solid dosage systems and turnkey oncology facilities — purpose-built infrastructure to bring cancer therapies to market faster.

Industry Overview

The Industry at a Glance

The global oncology drugs market was valued at USD 256.46 billion in 2025 and is projected to reach USD 697.59 billion by 2034, growing at a CAGR of 11.77%. This growth is driven by the rising global prevalence of cancer, increasing investments in oncology research, and advancements in biologics and targeted therapies, with the growing demand for personalized medicine and immunotherapy reshaping treatment protocols. As oncology pipelines expand across injectables, oral targeted therapies, and ADCs, manufacturers need GMP-compliant, scalable production infrastructure capable of handling complex formulations with strict containment and sterility requirements.

Product Applications

Where Our Products Are Used

  • 1

    IV Infusion Production Lines

    Complete systems for Non-PVC soft bag, PP bottle, and glass bottle IV solutions, from compounding to filling and sterilization.
  • 2

    Ampoule & Vial Filling Lines

    High-speed aseptic filling and sealing lines for injectable formulations, fully compliant with cGMP requirements.
  • 3

    Oral Solid Dosage (OSD) Plants

    Integrated granulation, tablet pressing, capsule filling, coating, and blister packaging for tablets and capsules.
  • 4

    Pharmaceutical Water Treatment Systems

    Purified water (PW) and water for injection (WFI) generation, storage, and distribution systems meeting pharmacopeia standards.
  • 5

    Cleanroom & HVAC Engineering

    Full facility design including classified cleanrooms, HVAC zoning, and environmental monitoring systems.

technology

Pain Points & Solutions

  • Pain Point: Oncology injectables demand ultra-strict aseptic processing — any contamination risk is unacceptable.

    Solution: Fully automated, enclosed filling lines with laminar flow isolation and CIP/SIP systems ensure sterility from vial entry to final seal.

  • Pain Point: Cytotoxic drug handling requires operator protection and cross-contamination prevention.

    Solution: Dedicated containment-ready OSD and injectable lines with closed transfer systems, negative-pressure zones, and segregated HVAC design.

  • Pain Point: Navigating multi-country GMP approvals delays facility commissioning and product

    Solution: All systems pre-engineered to EU GMP, US FDA cGMP, WHO GMP, and PIC/S standards — built for first-pass regulatory approval.

  • Pain Point: Scaling production from clinical-stage to commercial volumes strains existing capacity.

    Solution: Modular, expandable line architecture with full IQ/OQ/PQ validation enables seamless scale-up without rebuilding infrastructure.

Advantages

Why Choose Us

  • 2,500+ production lines delivered across 60+ countries — proven global oncology manufacturing expertise

  • 40+ turnkey projects completed — from process design through validated production handover

  • Multi-standard GMP compliance (EU, FDA, WHO, PIC/S) embedded in every system

  • 4 self-owned factories for pharma machinery, water treatment, cleanroom, and packaging — vertically integrated quality control

  • Full lifecycle service — consulting, engineering design, equipment manufacturing, installation, validation, technology transfer, and staff training

  • Containment-ready configurations for cytotoxic and high-potency oncology compounds

case

Success Snapshot

  • National Oncology Pharmaceutical Manufacturer

    Southeast Asia

    Delivered a complete injectable production facility including vial filling line, WFI system, and Grade A/B cleanroom. The plant passed WHO GMP inspection on the first audit and reached annual output of 15 million vials of chemotherapy injectables within 8 months of commissioning.

  • Leading Generic Oncology Company

    North Africa

    Supplied a turnkey oral solid dosage plant for oncology tablets and capsules with containment systems for cytotoxic APIs. The facility achieved EU GMP certification and began commercial production of 6 generic oncology products within the first year.

testimony

Trusted by Industry Leaders

  • “IVEN delivered our entire oncology injectable facility — from water systems to filling lines to cleanroom — all under one contract. Their team understood the containment requirements from day one, and we passed our WHO audit without a single critical finding.”

    Dr. A

    VP of Manufacturing

  • “We needed a partner who could handle cytotoxic OSD production with proper containment. IVEN’s integrated approach saved us 6 months versus coordinating multiple vendors, and the facility met EU GMP standards immediately.”

    Mr. K

    Technical Director

Support

FAQ

Yes. Our vial and ampoule lines are configurable for chemotherapy agents, monoclonal antibodies, ADCs, and other biologics with appropriate material contact parts and process parameters.

Absolutely. We provide containment-ready equipment, negative-pressure cleanroom design, and closed-system processing for high-potency oncology compounds.

All projects are designed to simultaneously meet EU GMP, US FDA cGMP, WHO GMP, and PIC/S GMP requirements.

Most projects are completed within 14–24 months from contract signing to validated commercial production, depending on facility scope and complexity.

Yes — including preventive maintenance programs, remote diagnostics, spare parts supply, process optimization, and on-site technical service.

Related Industry Solutions